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HTLV-I infection is associated with the development of adult T cell leukemia (ATL) and the neuroinflammatory disease HAM/TSP. There are
quantitative and qualitative differences in the antiviral cytotoxic T cell (CTL) response in ATL and HAM/TSP although the underlying
mechanisms are unclear. Here, we demonstrate that the HTLV-I Tax trans-activating protein is a transcriptional activator of CD40 ligand
(CD40L), a critical regulator of dendritic cell maturation and adaptive immunity. Tax activates CD40L expression via a cyclosporin A insensitive
pathway that is also independent of NF-κB. Although Tax upregulates CD40L gene expression, CD40L expression is absent in Tax-expressing
HTLV-I-transformed cell lines via an epigenetic mechanism involving methylation. T lymphocytes cultured ex vivo from ATL patients, but not
HAM/TSP or normal controls, exhibit a potent block in the induction of CD40L, but not CD69. However, the CD40L gene is not silenced by
methylation in ATL patients, thus CD40L is downregulated by distinct mechanisms in HTLV-I-transformed cell lines and ATL patients.
© 2007 Elsevier Inc. All rights reserved.Keywords: HTLV-I; Tax; ATL; HAM/TSP; CD40L; NFAT; NF-κB; Methylation; Gene expressionIntroduction
Human T cell leukemia virus type I (HTLV-I) infection is
associated with adult T cell leukemia (ATL) and a neuroin-
flammatory disease termed HTLV-I associated myelopathy/
tropical spastic paraparesis (HAM/TSP). The HTLV-I Tax
protein is a potent oncogene that regulates viral and cellular
gene expression and disrupts normal control of the cell cycle
(Jeang et al., 2004). Tax exerts its oncogenic activity, in part, by
modulating the expression of a large number of host genes,
particularly those involved in lymphocyte activation, survival
and transcription (Harhaj et al., 1999; Ng et al., 2001). The
effect of Tax on cellular gene expression is largely mediated by⁎ Corresponding author. Fax: +1 305 243 6410.
E-mail address: eharhaj@med.miami.edu (E.W. Harhaj).
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0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.12.020activation of signaling pathways such as NF-κB, CREB, AP-1
and nuclear factor of activated T cells (NFAT) (Hall and Fujii,
2005; Harhaj and Harhaj, 2005).
CD40 ligand (CD40L), or CD154, is a member of the tumor
necrosis factor (TNF) superfamily and interacts with CD40 to
mediate humoral and cellular immune responses against
pathogens (Foy et al., 1996). CD40L expression is mostly
restricted to activated T lymphocytes and is expressed
transiently whereas CD40 is expressed in a wide variety of
cells, including B lymphocytes and dendritic cells (DCs) (van
Kooten and Banchereau, 2000). Engagement of CD40 is
required for B cell maturation, survival and immunoglobulin
class switching (van Kooten and Banchereau, 2000). In DCs,
triggering of CD40 leads to maturation and efficient priming of
CD8+ T lymphocytes (Clarke, 2000). The importance of CD40
and CD40L for immune responses in vivo is underscored by the
genetic disease hyper-IgM syndrome caused by mutations in
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and impaired immunoglobulin isotype class switching (Aruffo
et al., 1993; Bhushan and Covey, 2001).
CD40L is expressed on activated naive T lymphocytes in
two distinct phases, early, which occurs within 24 h of antigen
receptor signaling, and late, which occurs after 24 h (Lee et al.,
2002). Cytokines such as IL-4 and IL-12 influence the
expression of CD40L during the late but not early phase (Lee
et al., 2002). Whereas IL-4 expression is associated with the
absence of CD40L during the late phase, IL-12 is associated
with prolonged expression of CD40L during the late phase (Lee
et al., 2002). Thus, the duration of CD40L expression is tightly
regulated and has important biological consequences. Increased
and prolonged expression of CD40L on activated T lympho-
cytes has been associated with autoimmune diseases such as
systemic lupus erythematosus (Koshy et al., 1996). Over-
expression of CD40L has also been associated with other
autoimmune diseases such as inflammatory bowel disease (IBD)
(Liu et al., 1999) and rheumatoid arthritis (MacDonald et al.,
1997). Conversely, a lack of CD40L expression in response to
anti-CD3 and anti-CD28 stimulation has been associated with
immunodeficiency which is observed with HIV-1 infection
(Zhang et al., 2004).
The transcription of CD40L is tightly regulated in activated
T lymphocytes. CD40L expression requires signals generated
from T cell antigen receptor signaling, including NFAT and NF-Fig. 1. HTLV-I Tax induces the expression of CD40L in JPX-9 cells. Tax expression
Tax-induced CD40L expression was analyzed at mRNA and protein levels. (A) Real
CdCl2. CD40L mRNA expression was normalized to expression of 18S rRNA in the
RT-PCR analysis of CD40L (top panel), CD40 (middle panel) and GAPDH (lower pan
CD40L protein expression in JPX-9 cells with or without CdCl2. Cells were stain
irrelevant antibody of the same isotype as the anti-CD40L antibody. At least 10,000
HTLV-I Tax was confirmed by Western blot analysis of JPX-9 whole cell lysates usκB (Cron, 2003). CD40L expression is potently inhibited by
cyclosporin A in activated primary T lymphocytes, suggesting a
requirement for the calcium responsive phosphatase calcineurin
which serves to dephosphorylate NFAT transcription factors,
leading to their nuclear localization (Fuleihan et al., 1994).
CD40L may also be regulated, in a coordinated manner with
CD40, by the AT-hook transcription factor AKNA (Siddiqa
et al., 2001). A recent study also supports a critical role for the
early growth response 1 (Egr-1) transcription factor in CD40L
expression (Cron et al., 2006). The CD40L upstream promoter
region, consisting of a 1.3 kb 5′-flanking region, contains cis-
elements for several transcription factors, including NFAT (Lobo
et al., 2000; Schubert et al., 1995), NF-κB (Srahna et al., 2001),
AP-1 (Tsytsykova et al., 1996) and Egr family members (Cron
et al., 2006). It is likely that optimal CD40L expression requires
the cooperation of multiple families of transcription factors that
converge on the CD40L promoter. An additional enhancer
composed of an NF-κB site has been identified in the 3′-flanking
region of the CD40L gene (Schubert et al., 2002). CD40L is also
regulated at the post-transcriptional level in activated T
lymphocytes where a complex of proteins assembles on the 3′
UTR region of CD40L mRNA and regulates stability of the
mRNA (Ford et al., 1999).
Whereas ATL patients exhibit immunodeficiency and in-
effective anti-HTLV-I cell-mediated immunity (Kozako et al.,
2006; Taguchi and Miyoshi, 1989), HAM/TSP patients ex-in JPX-9 cells was induced by incubating the cells with 15 μM CdCl2 for 24 h.
-time PCR analysis of CD40L mRNA expression in JPX-9 cells with or without
same real-time PCR reaction. The graph depicts the results of 3 experiments. (B)
el) mRNA expression in JPX-9 cells. (C) Flow cytometry analysis of cell surface
ed with PE-conjugated anti-CD40L antibody. Control cells were stained with
gated cells were analyzed for PE expression. (D) CdCl2 induced expression of
ing anti-Tax hybridoma supernatant.
Fig. 2. HTLV-I Tax induction of CD40L mRNA is independent of calcineurin
and NF-κB. (A) JPX-9 cells were untreated or stimulated with CdCl2 (15 μM)
and cyclosporin A (1 μg/ml) or sc-514 (25 μm) for 24 h. Real-time PCR for
CD40 was performed, and CD40 mRNA expression was normalized to 18S
rRNA in the same real-time PCR reaction. Error bars represent SEM, with n=3
for each condition. This experiment was repeated one additional time with
similar results. (B) JPX-9 cells were treated as in panel A, and real-time PCR
was performed for CD40L. CD40L mRNA expression was normalized to 18S
rRNA in the same real-time PCR reaction. (C) Jurkat-E6 cells were transfected
with 0.25 μg NFAT luciferase reporter and 0.01 μg pRL-TK luciferase.
Transfected cells were treated with or without PMA/ionomycin and cyclosporin
A for 7 h, harvested and a dual luciferase assay was performed. NFAT luciferase
values were normalized to renilla luciferase. Error bars represent SEM, with
n=3 for each condition.
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frequencies of circulating anti-HTLV-I CD8+ T cells (Kubota
et al., 2000). The mechanisms accounting for these highly
divergent immune responses in ATL and HAM/TSP are largely
unknown. We hypothesize that distinct patterns of gene
expression in infected cells from ATL and HAM/TSP patients
may play a role in disease progression and pathogenesis. We
have previously demonstrated that CD40 is aberrantly expressed
in HTLV-I-transformed cell lines and is upregulated by Tax
(Harhaj et al., 2005). In a gene array analysis in our previous
study, we also observed that CD40L may be regulated by Tax
(Harhaj et al., 2005). In this report, we demonstrate that Tax is a
transcriptional regulator of the CD40L gene. Surprisingly, Tax
upregulates CD40L expression in a cyclosporin A insensitive
manner. Furthermore, CD40L expression is absent in Tax-
expressing HTLV-I-transformed cell lines due to an epigenetic
mechanism involving methylation. In ATL, but not HAM/TSP
patients, there is a profound block in the induction of CD40L,
but not CD69, in PBMCs stimulated ex vivo that does not
appear to be mediated by epigenetic mechanisms. These
results may help explain the severe immunodeficiency and
defective antiviral CTL responses commonly observed in ATL
patients.
Results
Tax upregulates the expression of CD40L mRNA and protein
Tax promotes the uncontrolled proliferation and immortali-
zation of T lymphocytes by deregulating cellular signaling
pathways and gene expression. In a previous study from our
laboratory, we used gene array analysis to identify several genes
from the TNF/TNFR superfamilies that may be regulated by
Tax (Harhaj et al., 2005). One of the putative Tax regulated
genes was CD40L, an important costimulatory molecule
expressed on activated T lymphocytes that galvanizes adaptive
immune responses. To confirm that Tax was indeed upregulat-
ing the expression of CD40L, we used the Tax-inducible Jurkat
subline JPX-9 which stably expresses Tax under the control of a
metallothionein promoter (Fujii et al., 1991). JPX-9 cells were
treated with CdCl2 for 24 h to induce Tax expression and total
RNAwas isolated from the cells for real-time RT-PCR analysis.
CD40L mRNA was upregulated by Tax as demonstrated by
real-time RT-PCR (Fig. 1A) and RT-PCR (Fig. 1B). Further-
more, we used flow cytometry to demonstrate that CD40L
protein was upregulated on the cell surface of CdCl2-treated
JPX-9 cells (Fig. 1C). As expected, Tax expression was induced
by CdCl2 treatment (Fig. 1D).
Tax-mediated upregulation of CD40L does not require NF-κB
and is insensitive to cyclosporin A
To determine the signaling pathways that governed Tax-
induced CD40L induction, we used pharmacological inhibitors
of NF-κB and calcineurin, sc-514 and cyclosporin A (CsA)
respectively. CD40L mRNA is strongly induced in activated T
lymphocytes and requires multiple signals including calciumsignaling that promotes calcineurin-dependent NFAT activation
(Cron, 2003). Treatment of activated T lymphocytes with CsA
leads to potent inhibition of CD40L transcription (Fuleihan
et al., 1994). In addition, NF-κB has been reported to play a role
in CD40L expression induced by antigen receptor signaling
(Srahna et al., 2001). To determine if Tax required calcineurin for
the induction of CD40L, we treated JPX-9 cells with CdCl2 to
induce Tax expression in the absence or presence of CsA
followed by real-time RT-PCR analysis. As seen in Fig. 2B, Tax
expression resulted in about a six-fold increase in CD40L
mRNA, and surprisingly CsA had no effect on Tax-mediated
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NFAT-Luc reporter activated by PMA and ionomycin (Fig. 2C).
To examine the role of NF-κB in Tax-mediated CD40L
upregulation, we treated JPX-9 cells with the IKK inhibitor sc-
514 (Jeong et al., 2005). Although sc-514 inhibited Tax
induction of CD40 (Fig. 2A), a known NF-κB-dependent Tax
target, it had little, if any, effect on Tax upregulation of CD40L
(Fig. 2B). These results indicate that Tax requires neither
calcineurin nor NF-κB to activate CD40L expression. We also
found that Tax activated the CD40L promoter (a 5 kb fragment
upstream of the transcriptional start site) by 2- to 3-fold in an
NFAT and NF-κB independent manner (data not shown).Fig. 3. CD40L is silenced by methylation, but not deacetylation, in Tax-expressing
expression in C8166, MT-2, SLB-1 and HUT-102 HTLV-I-infected T cell lines and
treatment. Bars represent relative CD40L mRNA levels normalized to 18S rRNA
GAPDH expression in C8166 cells treated with or without trichostatin A (100 nM) fo
CD40L protein in C8166 and MT-2 HTLV-I-infected T cell lines with or without treat
Cells were stained with PE-conjugated anti-CD40L antibody. Control cells were stain
expression was analyzed on 10,000 gated cells using FACScan flow cytometer. (D) R
with or without 5-aza-2′-deoxycytidine (1 μM) for 72 h and PMA and/or ionomycin
OM1 cells infected with either pCLXSN or pCLXSN-Tax. Cells were treated overn
with PMA/ionomycin, 5-aza-dc (1 μm) for 3 days either alone or together with PMCD40L expression is silenced by methylation in Tax-expressing
HTLV-I-transformed cell lines
We then analyzed CD40L expression in HTLV-I-transformed
cell lines by real-time RT-PCR. There was no CD40L mRNA
detected in all of the HTLV-I-transformed cell lines, including
SLB-1, HUT-102, C8166 and MT-2 (Fig. 3A). CD40L protein
was also absent from the cell surface of these cell lines (data not
shown). These results are in agreement with our previous study
demonstrating that CD40L is downregulated in immortalized T
lymphocytes using an in vitro coculture model of HTLV-I
infection (Harhaj et al., 1999). As expected, we readily detectedHTLV-I-infected T cell lines. (A) Real-time PCR analysis of CD40L mRNA
Jurkat cells non-treated and activated by PMA (10 ng/ml)/ionomycin (2 μM)
in the same real-time PCR reaction. (B) RT-PCR analysis of CD40L, Tax and
r 72 h and PMA and/or ionomycin for the last 6 h. (C) Cell surface expression of
ment with PMA and ionomycin for 6 h and/or Trichostatin A (500 nM) for 24 h.
ed with irrelevant antibody of the same isotype as the anti-CD40L antibody. PE
T-PCR analysis of CD40L, Tax and GAPDH expression in C8166 cells treated
for the last 6 h. (E) RT-PCR analysis of CD40L, Tax, CD69 and GAPDH in TL-
ight with either PMA/ionomycin alone, TSA (500 nM) alone or in combination
A/ionomycin overnight.
Fig. 4. CD40L, but not CD69, induction is defective in peripheral blood
mononuclear cells of ATL patients. (A) Flow cytometry analysis of CD40L and
CD4 cell surface expression in PBMCs obtained from normal and ATL or HAM/
TSP patients. Cells were either untreated or treated overnight with PMA (10 ng/
ml) and ionomycin (2 μM). Cells were stained with PE-conjugated anti-CD40L
antibody, PE-Cy5-conjugated anti-CD25 and FITC-conjugated anti-CD4 anti-
body. The data are presented as a two-dimensional dot plot depicting cells that
were within the gated region of the light scattering plot. Gating was done using
FSC and SSC properties, and for each test, at least 10,000 gated cells were
analyzed. The numbers in each panel denote the percentage of cells falling
within the indicated regions. (B) Flow cytometry analysis of PBMCs from an
acute ATL patient. Cells were treated as in panel A and stained with either PE-
conjugated anti-CD40L or anti-CD69 together with PE-Cy5-conjugated anti-
CD25 and FITC-conjugated anti-CD4 antibody. Analysis was performed as
described in panel A.
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treated with PMA and ionomycin (Fig. 3A). CD40L mRNAwas
also not expressed when HTLV-I-transformed cell lines were
treated with PMA and ionomycin (Fig. 3B). We hypothesized
that the CD40L gene may be silenced by an epigenetic
mechanism in these cell lines. Histone deacetylation and
methylation are two common mechanisms of epigenetic
silencing of genes (Baylin and Ohm, 2006). To determine if
CD40L was silenced by histone deacetylation, we treated cells
with the HDAC inhibitor trichostatin A (TSA). Treatment of
C8166 and MT-2 cells with either TSA alone or in combination
with PMA and ionomycin did not restore CD40L expression
(Figs. 3B and C). However, when C8166 cells were treated with
the demethylating agent 5-aza-dc together with ionomycin but
not PMA, CD40L expression was restored (Fig. 3D). When
cells were treated with 5-aza-dc together with both PMA and
ionomycin, the restoration of CD40L was even more dramatic
(Fig. 3D). In MT-2 cells, 5-aza-dc together with PMA and
ionomycin also induced CD40L, although not to the same
degree as C8166 cells (data not shown). These results suggest
that CD40L is silenced by methylation, but not deacetylation, in
Tax-expressing HTLV-I-transformed cell lines. Furthermore, it
is apparent that Tax expression is no longer sufficient for
CD40L upregulation in these cells in the presence of 5-aza-dc
since PMA and ionomycin treatment is also required.
To determine the exact role of Tax in CD40L induction by 5-
aza-dc and PMA/ionomycin, we next examined TL-OM1 cells
which are leukemic cells derived from an ATL patient. This cell
line may be more representative of ATL tumors since it lacks
Tax expression but retains constitutive NF-κB activation
(Hironaka et al., 2004). TL-OM1 cells were infected with a
Tax-expressing retroviral vector (pCLXSN-Tax) or empty
vector (pCLXSN). After infection, cells were treated with
either PMA/ionomycin, 5-aza-dc or TSA with and without
PMA/ionomycin. Surprisingly, CD40L expression was unable
to be restored with any of the conditions, either in empty vector
or Tax-infected cells (Fig. 3E). The housekeeping gene GAPDH
was similarly expressed in all of the samples. CD69 was
significantly upregulated after TSA and PMA/ionomycin
treatment, especially in the presence of Tax (Fig. 3E). Thus,
at least in TL-OM1 cells, CD40L expression is unable to be
restored by 5-aza-dc, TSA or Tax expression.
T lymphocytes stimulated ex vivo from ATL, but not HAM/TSP
patients, exhibit a potent defect in CD40L induction
We next examined CD40L expression in HTLV-I-infected
patients. PBMCs were isolated from ATL, HAM/TSP or
uninfected normal donors and stained with antibodies for flow
cytometry experiments. In normal donors, CD40L was not
expressed on resting cells, but was induced after treatment with
PMA and ionomycin (Fig. 4A). In HAM/TSP patients (a total of
two were examined), there was a normal induction of CD40L by
PMA and ionomycin within CD4+CD25+ lymphocytes (Fig.
4A). However, there was a profound block of CD40L
expression in response to PMA and ionomycin treatment in
an ATL patient (acute ATL; white blood cell count (WBC)
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induction of CD40L was also observed in three other ATL
patients we examined, two of which were diagnosed with acute
ATL (WBC 42,000 and 68,000 cells/mm3) and the other with
unfavorable chronic ATL (WBC 45,000 cells/mm3). Impor-tantly, defective CD40L induction was not observed in any
normal controls or HAM/TSP patients. Interestingly, mitogen-
induced activation of CD69, which only requires PMA
stimulation (Taylor-Fishwick and Siegel, 1995), was unaffected
in ATL patients (Fig. 4B). Downregulation of CD4, which is
dependent on PMA stimulation (Bigby et al., 1990), was
similarly unaffected in ATL (Fig. 4A). These results raise the
intriguing possibility that calcium signaling may be defective in
ATL patients. Furthermore, the block in CD40L induction is
specific for ATL patients in the context of HTLV-I infection.
To determine if the expression of CD40L was downregulated
by methylation in ATL patients, we obtained PBMCs from the
same ATL patient shown in Fig. 4A at a later time and treated
with 5-aza-dc for 72 h together with PMA and ionomycin
treatment for the final 12 h of culture. First, we confirmed that
ex vivo stimulation of these cells with PMA and ionomycin for
12 h did not result in efficient induction of CD40L (Fig. 5A, top
panel). Treatment of cells with 5-aza-dc alone for 72 h was
unable to induce CD40L expression in ATL cells (Fig. 5A).
However, PMA and ionomycin treatment resulted in a robust
induction of CD40L, but only after cells were cultured for 72 h
(Fig. 5A). It has been reported that the tax gene is silenced,
mutated or absent in vivo in ATL patients (Takeda et al., 2004).
We performed immunoblotting for Tax from the same ATL
patient at different time points in cell culture, and Tax was
clearly absent in PBMCs ex vivo but was expressed after
culturing the cells for 24 and 72 h (Fig. 5B). Thus, Tax
expression, or possibly another factor induced by culturing the
cells in vitro, may be essential to restore the normal induction of
CD40L expression in ATL patients.
Discussion
In this study, we have demonstrated that the HTLV-I Tax
oncoprotein is a transcriptional regulator of CD40L. Tax
expression correlates with the upregulation of CD40L mRNA
and protein in T lymphocytes. However, Tax appears to use
mechanisms distinct from T cell antigen receptor signaling to
induce CD40L since it requires neither calcineurin nor NF-κB
for upregulation of CD40L mRNA. In certain Tax-expressing
HTLV-I-transformed cell lines such as C8166, CD40L is absent
due to epigenetic silencing by methylation. In other HTLV-I-
transformed cell lines that lack Tax expression such as TL-
OM1, CD40L is likely downregulated by distinct mechanisms.
We also examined the expression of CD40L in patients infected
with HTLV-I and observed defective CD40L induction in
response to mitogens in ATL but not HAM/TSP patients.Fig. 5. CD40L is not silenced by methylation in ATL patients. (A) PBMCs from
an ATL patient were either untreated or treated overnight with PMA and
ionomycin and subjected to flow cytometry (top panel). PBMCs from the same
ATL patient or normal control were either untreated or incubated with 5-aza-2′-
deoxycytidine (1 μM) for 72 h and/or PMA and ionomycin for the final 12 h
(bottom panel). Cells were stained and analyzed as in panel A. (B) PBMCs
obtained from the same ATL patient used in panels A and B were incubated at
37 °C and 5% CO2 for 0, 24 and 72 h. Whole cell lysates were subjected to
SDS–PAGE and Western blot analysis was performed with anti-Tax (top panel)
or anti-β-actin antibodies (lower panel).
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patients and can be restored by mitogen treatment after culturing
the cells for 72 h, coincident with induction of Tax. Thus,
CD40L is dysregulated by distinct mechanisms in HTLV-I-
transformed cell lines and ATL patients.
The transcriptional regulation of the CD40L gene in
response to antigen receptor signaling in T lymphocytes has
been extensively studied (Cron, 2003). It is well established that
CD40L requires multiple signals for its activation, with one of
the most critical ones being calcium signaling that mediates
NFAT activation (Fuleihan et al., 1994). In addition to NFAT,
there have been reports that NF-κB (Srahna et al., 2001), AP-1
(Tsytsykova et al., 1996) and Egr-1 (Cron et al., 2006) also play
important roles in CD40L regulation. We are currently directing
our efforts to identify factors essential for Tax activation of
CD40L. Clearly, Tax upregulation of CD40L mRNA occurs in
the absence of NFAT and NF-κB activation. Therefore, Tax
induction of CD40L is the first known example, to our
knowledge, of transcriptional upregulation of the CD40L gene
in a cyclosporin A insensitive manner. It is unknown why Tax
would acquire a mechanism for CD40L induction that is distinct
from antigen receptor signaling and independent of NFAT or
NF-κB. Tax is a potent activator of NF-κB, and activation of
NF-κB is a hallmark of HTLV-I-transformed cell lines and ATL
patients (Sun and Yamaoka, 2005). Furthermore, Tax activates
NFAT by promoting the dephosphorylation and nuclear
translocation of NFAT1 in a cyclosporin A sensitive manner,
and NFAT1 is constitutively activated in HTLV-I-transformed
cell lines (Good et al., 1997). It is possible that HTLV-I may
require CD40L in a transient manner for a function related to the
viral life cycle and therefore may not need constitutive
expression of CD40L, which would occur in cells with
constitutive NF-κB and NFAT activation. Furthermore, con-
stitutive expression of CD40L may lead to hyperstimulation of
antiviral immune responses and autoimmunity, similar to what
is observed in HAM/TSP. However, we did not observe
constitutive expression of CD40L in the small number of
HAM/TSP patients we examined, although the basal levels of
CD40L were slightly higher compared to uninfected control
PBMCs (Fig. 4A).
We have found that CD40L expression is downregulated by
an epigenetic mechanism involving methylation in certain Tax-
expressing HTLV-I-transformed cell lines. CD40L expression is
restored upon treating HTLV-I-transformed C8166 cells with 5-
aza-dc in combination with PMA and ionomycin. It is unclear
why treatment with 5-aza-dc alone is not sufficient to rescue
CD40L expression in these cells since Tax is highly expressed
in these cell lines. These results would imply that Tax regulation
of CD40L expression is uncoupled in HTLV-I-transformed cell
lines. This notion is further supported by our results with the
TL-OM1 cell line that lacks Tax expression. Retroviral-vector-
mediated introduction of Tax in these cells was unable to induce
CD40L expression, even in the presence of 5-aza-dc and PMA/
ionomycin treatment (Fig. 3E). Thus, it appears that there are
distinct mechanisms of CD40L downregulation in different
HTLV-I-transformed cell lines, although the exact mechanism
of CD40L downregulation in TL-OM1 cells or ATL patients isuncertain. Furthermore, it is unclear if the cd40l gene is directly
silenced by methylation or indirectly by silencing of a regulator
of cd40l gene expression. Aberrant methylation of CpG islands
in gene promoters is a common mechanism of gene inactivation
in the progression of many cancers (Baylin and Ohm, 2006).
The cd40l gene, to our knowledge, has not been identified
previously as a direct target of methylation. The cd40l genomic
region, including the promoter (up to 5 kb upstream of the start
site) and exon/intron sequences, is devoid of CpG islands, thus
CD40L may not be a direct target for methylation. One
candidate for an upstream regulator of CD40L that may be
silenced is egr3, which has been shown to be silenced directly
by methylation in ATL patients (Yasunaga et al., 2004).
However, it is unlikely that downregulation of egr family
members is linked to CD40L silencing in HTLV-I-transformed
cell lines since we found that egr1–3 are indeed expressed in
C8166 cells (data not shown).
A previous study examined CD40L expression in T
lymphocytes derived from HAM/TSP and ATL patients that
were cultured in vitro in the presence of PHA and IL-2 (Makino
et al., 2001). Makino et al. demonstrated that CD40L expression
is significantly lower on CD4+ T lymphocytes from ATL versus
HAM/TSP patients after culturing for 1 and 3 weeks, although
they did not determine if Tax was expressed in their cultured
cells (Makino et al., 2001). Our current study indicates that
there is a potent block in the induction of CD40L ex vivo,
selectively in ATL but not HAM/TSP patient PBMCs. Culturing
ATL PBMCs in vitro leads to a progressive increase in Tax
expression which may endow cells with the capacity to
upregulate CD40L in response to mitogen stimulation. A recent
report has indicated that ATL patients exhibit reduced fre-
quency, diversity and function of HTLV-I-specific CD8+ T cells
(Kozako et al., 2006). It is tempting to speculate that the lack of
CD40L induction in ATL patients may be linked to the reduced
and defective anti-HTLV-I CTLs in these patients. Future
studies will be necessary to confirm this hypothesis. In addition,
it is necessary to identify the mechanism underlying the defect
in CD40L expression in ATL patients. This observation is
reminiscent of the defect in CD40L induction observed in
HIV-1-infected patients (Chougnet, 2003). However, the defect
is likely distinct in HIV-1 infection since PMA/ionomycin, but
not anti-CD3/CD28, induces CD40L expression in CD4+ T
cells from HIV-1-infected patients. Anergic T lymphocytes also
exhibit a defect in CD40L expression (Bowen et al., 1995), thus
an intriguing possibility is that T lymphocytes from ATL
patients may be functionally anergic. This may explain why
ATL patients are prone to opportunistic infections.
CD40L expression does not appear to be downregulated by
methylation in ATL patients, indicating that HTLV-I-trans-
formed cell lines such as C8166 or MT-2 may not be very
representative of ATL tumors in vivo. TL-OM1 cells, which
lack Tax expression, may be more representative of ATL with
regard to CD40L downregulation. Introduction of Tax into these
cells did not restore CD40L expression, even combined with
PMA/ionomycin and 5-aza-dc stimulation. Thus, Tax likely
does not play a role in the restoration of silenced CD40L in
HTLV-I-transformed cell lines. However, one caveat is that the
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retroviral infection may not have been high enough to restore
CD40L expression. It is known that ATL tumors do not express
Tax in vivo, but in vitro culturing of ATL PBMCs leads to a
progressive increase in Tax expression over time. Thus, it is
critical to perform experiments with unmanipulated ATL tumors
to circumvent potential artifacts associated with Tax expression.
Besides CD40L, we have not observed a defect in mitogen-
induced activation of other genes in ATL patients, suggesting a
strict selectivity, although future studies with gene arrays are
necessary to confirm this hypothesis. CD69 induction was
normal in ATL PBMCs treated with PMA and ionomycin (Fig.
4B). Interestingly, CD69 activation does not require calcium
signaling but only a PKC-mediated signal generated by PMA
(Taylor-Fishwick and Siegel, 1995). Furthermore, PMA-
mediated downregulation of CD4 was normal in the ATL
patients. These results indicate that the defect in ATL patients
may be linked to a defective calcium signaling pathway or
impaired induction of calcium-regulated genes. Future studies
will examine the efficiency of calcium mobilization and the
induction of calcium-regulated genes in T lymphocytes from
ATL patients.
Materials and methods
Biological reagents and cell culture
The human T cell lymphocytic cell lines Jurkat and JPX-9
(kindly provided by Drs. Naoki Mori and Masataka Nakamura),
the Tax-expressing HTLV-I-transformed T cell lines C8166,
MT-2, SLB-1, and HUT-102, and the ATL cell line lacking Tax
expression, TL-OM1 (kindly provided by Dr. Michiyuki
Maeda), were cultured and maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum (HyClone Labora-
tories, Logan, UT). JPX-9 cells are subclones of Jurkat cells that
stably express the tax gene under the control of a metallothio-
nein promoter (Fujii et al., 1991). Peripheral blood was obtained
from normal donors, ATL and HAM/TSP patients after
informed consent, approved by the University of Miami
Institutional Review Board. Clinical diagnosis of ATL was
made by serologic evidence of HTLV-I by ELISA, confirmed by
Western blot, and the identification of circulating leukemic cells
of T cell origin by morphology, flow cytometry and gene
rearrangement, performed at Jackson Memorial Hospital
(JMH)/University of Miami. ATL patients were subclassified
as acute-type leukemia as per Shimoyama (1991). Clinical
diagnosis of HAM/TSP was made by neurologic symptoms,
imaging studies and HTLV-I serology. HAM/TSP patients were
diagnosed outside of JMH and referred to our center. Peripheral
blood mononuclear cells (PBMCs) were obtained by density
gradient centrifugation using Ficoll-Paque Plus (GE Healthcare
Biosciences Corp., Piscataway, NJ). The anti-CD40L-phycoer-
ythrin (PE) (TRAP1 clone), anti-CD69-PE (clone FN50), anti-
CD4-FITC (clone RPA-T4), anti-CD25-PE-Cy5 (clone M-
A251) and anti-mouse IgG PE, FITC and PE-Cy5 isotype
control antibodies were purchased from BD Pharmingen (San
Diego, CA). The Tax monoclonal antibody was prepared from aTax hybridoma (NIH AIDS Research and Reagents Program).
The monoclonal β-actin antibody was purchased from AbCam
(Cambridge, MA). Trichostatin A (TSA), 5-aza-dc, CdCl2 and
cyclosporin A (CsA) were purchased from Sigma (St. Louis,
MO). The IKK inhibitor sc-514 was purchased from EMD
Biosciences (San Diego, CA).
Luciferase assays and transient expression analysis
Transient transfections in Jurkat cells were performed with
the FuGENE 6 transfection reagent (Roche, Indianapolis, IN) as
described previously (Harhaj et al., 2005). Transfections with
NFAT-Luc (BD Biosciences) also included pRL-tK (25 ng) to
normalize for transfection efficiency. Dual luciferase assays
were performed according to the manufacturer's instructions
(Promega, Madison, WI). Data are represented as fold induction
of PMA and ionomycin treatment versus no treatment after
normalization with pRL-tK values. Error bars indicate the
standard error of the mean (SEM) of triplicate samples.
Flow cytometry
Cells (5×105) were incubated with 10 μl of individual PE-
conjugated or isotype control antibodies for 30 min in 100 μl of
FACS buffer (PBS, 0.05% NaN3, 3% FBS) on ice. Cells were
washed once with ice-cold FACS buffer, washed again with ice-
cold PBS, and resuspended in 300 μl of 2% paraformaldehyde.
Fluorescence-activated flow cytometry was performed with a
FACScan 2000 (Becton Dickinson, Franklin Lakes, NJ) flow
cytometer. A total of 10,000 events were analyzed for each
sample. Live cells were gated for analysis based on forward
angle light scatter (FSC) and side angle light scatter (SSC).
Single-color and three-color analyses were performed with
CellQuest software (Becton Dickinson) and Windows Multiple
Document Interface flow cytometry application (WinMDI).
Cells from normal donors, ATL and HAM/TSP patients were
gated on CD4+CD25+ cells.
RT-PCR
Total RNA was isolated from cells using an RNeasy kit
(Qiagen, Valencia, CA) as recommended by the manufacturer.
A total of 2 μg of RNA was converted to cDNA in a reverse
transcriptase (RT) reaction using the first strand cDNA
synthesis kit for RT-PCR (AMV; Roche; Indianapolis, IN).
Reactions were primed with random primers (Roche). RT-PCR
was performed to amplify the indicated genes in a 50 μl reaction
containing 2 μl of cDNA, 1× PCR buffer (Invitrogen), 0.25 μM
of forward and reverse primers, 0.2 mM dNTP mix, 1.5 mM
MgCl2 and 3 units of Platinum Taq polymerase (Invitrogen).
PCR products were resolved by agarose gel electrophoresis.
The following sets of primers were used to amplify gene
products for RT-PCR reactions: glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (263 bp) forward-5′-CCACAGT
CCATGCCATCAC, reverse-5′-GCTTCACCACCTTCTT-
GATG; Tax (429 bp) forward-5′-CGGATACCCAGTC-
TACGTC, reverse-5′-GAGGTACATGCAGACAACGG; CD40
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5′-CACTGTCTCTCCTGCACTGAG; CD40L (785 bp) for-
ward-5′ CAT GAT CGA AAC ATA CAA CCA AAC, reverse-
5′-CAG AGT TTG AGT AAG CCA AAG G; CD69 (492 bp)
forward-5′-CGTAGCAGAGAACAGCTCTTTG, reverse-5′-
GTCAGACCCTGTAACGTTGAAC.
Quantitative real-time RT-PCR
Total RNA was converted to cDNA as described above, and
1 μl of cDNAwas used as a template in subsequent PCR reaction
that was performed on LightCycler Instrument (Roche Diagnos-
tics) using LightCycler TaqMan Master kit (Roche) and gene
specific Hydrolysis (TaqMan) Probes, according to the manufac-
turer's instruction. TaqMan probes for CD40 and CD40L were
purchased from Applied Biosystems (Foster City, CA). We used
18S rRNA as an internal control for relative gene expression
quantification and for each gene amplification, Cp values (reading
obtained at 530 nm) were normalized to the Cp of the 18S rRNA
(reading obtained at 560 nm) using calibrator normalized relative
quantification in the LightCycler analysis software.
Retroviral vector infections
Retroviral infections were performed as described (Harhaj
et al., 2005; Naviaux et al., 1996; Rivera-Walsh et al., 2001).
Briefly, 293T cells were transfected with 1 μg of either
pCLXSN or pCLXSN-Tax together with pCL-Ampho (1 μg)
and VSV-g (0.15 μg) using FuGENE 6 (Roche). Supernatant
containing recombinant retroviruses was filtered 36 h post-
transfection using a 0.45 μM polysulfone filter (Pall-Gelman
Acrodisc) and used to resuspend TL-OM1 cells in 6-well
plates. Polybrene (8 μg/ml; Sigma) was added to each well,
and cells were centrifuged at 1800 rpm for 45 min. The cells
were washed with RPMI media the following day, and the 5-
aza-dc treatments were initiated the next day.
Western blotting
Western blotting was performed as described previously
(Harhaj and Sun, 1999). Cells were lysed in RIPA buffer and
proteins were resolved by SDS–polyacrylamide gel electro-
phoresis (PAGE) and transferred to nitrocellulose membranes.
Membranes were blocked in 5% milk, incubated with primary
antibodies (anti-Tax 1:1000 dilution and anti-β-actin 1:5000
dilution), washed three times with PBST, incubated with mouse
Ig-horse radish peroxidase (HRP)-conjugated antibody (GE
Healthcare, Piscataway, NJ), washed three times with PBST and
antigen–antibody complexes were detected with Western
Lightning Enhanced Chemiluminescence (ECL) reagent (Per-
kin Elmer, Boston, MA).Acknowledgments
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